Literature DB >> 11744606

The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies.

George Hill1, Tomas Cihlar, Charles Oo, Edmund S Ho, Ken Prior, Hugh Wiltshire, Jo Barrett, Baulian Liu, Penny Ward.   

Abstract

Oseltamivir is an ester prodrug of the active metabolite [3R,4R,5S]-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a potent and selective inhibitor of neuraminidase enzyme of influenza virus. Oseltamivir is rapidly hydrolyzed by hepatic carboxylesterases to Ro 64-0802, which is then exclusively excreted by glomerular filtration and active tubular secretion without further metabolism. In vivo and in vitro studies were conducted to evaluate the renal drug-drug interaction potential of oseltamivir. Crossover studies were conducted in healthy subjects in which oral oseltamivir was administered alone and coadministered with probenecid, cimetidine, or amoxicillin. Probenecid completely blocked the renal secretion of Ro 64-0802, increasing systemic exposure (area under the curve) by 2.5-fold, but no interaction was observed with cimetidine or amoxicillin. These in vivo data show that Ro 64-0802 is secreted via an organic anion pathway, but Ro 64-0802 does not inhibit amoxicillin renal secretion. In vitro effects of Ro 64-0802 on the human renal organic anionic transporter 1 (hOAT1) were investigated using novel Chinese hamster ovary cells stably transfected with hOAT1. Ro 64-0802 was found to be a low-efficiency substrate for hOAT1 and a very weak inhibitor of hOAT1-mediated transport of p-aminohippuric acid (PAH). Ro 64-0802 did not inhibit the hOAT1-mediated transport of amoxicillin. In contrast, probenecid effectively inhibited the transport of PAH, Ro 64-0802, and amoxicillin via hOAT1. These in vitro observations are consistent with the in vivo data, validating the usefulness of the in vitro system for evaluating such drug-drug interaction. The study results demonstrate that oseltamivir has a low drug-drug interaction potential at the renal tubular level due to inhibition of hOAT1.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11744606     DOI: 10.1124/dmd.30.1.13

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  33 in total

1.  Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin.

Authors:  Charles Oo; Joanne Barrett; Albert Dorr; Baolian Liu; Penelope Ward
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 2.  Oseltamivir in seasonal, avian H5N1 and pandemic 2009 A/H1N1 influenza: pharmacokinetic and pharmacodynamic characteristics.

Authors:  Nicolas Widmer; Pascal Meylan; Anton Ivanyuk; Manel Aouri; Laurent A Decosterd; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

Review 3.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

4.  Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants.

Authors:  Neil Parrott; Brian Davies; Gerhard Hoffmann; Annette Koerner; Thierry Lave; Eric Prinssen; Elizabeth Theogaraj; Thomas Singer
Journal:  Clin Pharmacokinet       Date:  2011-09       Impact factor: 6.447

5.  Sotalol-induced torsades de pointes precipitated during treatment with oseltamivir for H1N1 influenza.

Authors:  Quinn Wells; Bradley Hardin; Satish R Raj; Dawood Darbar
Journal:  Heart Rhythm       Date:  2010-07-23       Impact factor: 6.343

Review 6.  Towards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulations.

Authors:  Vicky Hsu; Manuela de L T Vieira; Ping Zhao; Lei Zhang; Jenny Huimin Zheng; Anna Nordmark; Eva Gil Berglund; Kathleen M Giacomini; Shiew-Mei Huang
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

7.  Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteers.

Authors:  S S Jhee; M Yen; L Ereshefsky; M Leibowitz; M Schulte; B Kaeser; L Boak; A Patel; G Hoffmann; E P Prinssen; C R Rayner
Journal:  Antimicrob Agents Chemother       Date:  2008-08-01       Impact factor: 5.191

Review 8.  Oseltamivir in human avian influenza infection.

Authors:  James R Smith
Journal:  J Antimicrob Chemother       Date:  2010-04       Impact factor: 5.790

Review 9.  Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations.

Authors:  Brian E Davies
Journal:  J Antimicrob Chemother       Date:  2010-04       Impact factor: 5.790

10.  Pharmacokinetics of high-dose oseltamivir in healthy volunteers.

Authors:  Y Wattanagoon; K Stepniewska; N Lindegårdh; S Pukrittayakamee; U Silachamroon; W Piyaphanee; T Singtoroj; W Hanpithakpong; G Davies; J Tarning; W Pongtavornpinyo; C Fukuda; P Singhasivanon; N P J Day; N J White
Journal:  Antimicrob Agents Chemother       Date:  2008-12-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.